title: Langerhans cell histiocytosis of the uvea with neovascular glaucoma: diagnosis by fine-needle aspiration biopsy and management with intraocular bevacizumab and brachytherapy.
abstract: A 6-year-old boy with known multisystem Langerhans cell histiocytosis developed photophobia, conjunctival injection, iris neovascularization, and an iridociliochoroidal mass. Fine-needle aspiration biopsy revealed mononucleated and multinucleate histiocytes that demonstrated positive immunostaining for CD68 and S100 consistent with Langerhans cell histiocytosis. Management with intracameral bevacizumab (1.25 mg/0.05 mL) resolved the iris neovascularization, and plaque radiotherapy (brachytherapy) resolved the mass rapidly and completely, preserving the patient's visual acuity and preventing glaucoma during the 10-month follow-up.
authors.affiliation: Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. carol.shields@shieldsoncology.com
authors.forename: Carol L
authors.initials: CL
authors.lastname: Shields
authors.forename: Michael D
authors.initials: MD
authors.lastname: Hogarty
authors.forename: Brad E
authors.initials: BE
authors.lastname: Kligman
authors.forename: Colleen
authors.initials: C
authors.lastname: Christian
authors.forename: Hormoz
authors.initials: H
authors.lastname: Ehya
authors.forename: Jerry A
authors.initials: JA
authors.lastname: Shields
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D044963:Biopsy, Fine-Needle; D001918:Brachytherapy; D002648:Child; D003131:Combined Modality Therapy; D015355:Glaucoma, Neovascular / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D056965:Injections, Intraocular; D008297:Male; D014602:Uvea / Q000473:pathology*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab